Trident Texofab Limited has announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025, following the board meeting held on February 12, 2026. The company demonstrated strong financial performance with significant improvement in profitability metrics across both quarterly and nine-month periods.

Financial Performance Overview

The company's financial results show mixed performance in revenue generation but substantial improvement in profitability. For the quarter ended December 31, 2025, total income reached ₹2,621.95 lakhs compared to ₹3,143.23 lakhs in the corresponding quarter of the previous year.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, the company maintained steady revenue performance while achieving remarkable profit growth. Total income for the nine-month period stood at ₹8,576.10 lakhs compared to ₹8,722.06 lakhs in the previous year.

Cost Management and Operational Efficiency

The company demonstrated improved cost management during the quarter. Total expenses decreased to ₹2,537.88 lakhs from ₹3,116.19 lakhs in the corresponding quarter of the previous year. Key expense categories showed varying trends, with purchases of stock-in-trade representing the largest expense component at ₹1,799.18 lakhs for the quarter.

Regulatory Compliance and Governance

The financial results were prepared in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the audit committee and subsequently approved by the board of directors. Shah Kailash & Associates LLP, the company's statutory auditors, issued a limited review report confirming compliance with applicable accounting standards and regulatory requirements.

Business Operations and Segment Performance

Trident Texofab Limited operates in a single reportable business segment focused on manufacturing and wholesale trading of grey cloth. The company maintains its registered office operations and continues to demonstrate operational resilience in the textile manufacturing sector. Company Secretary and Compliance Officer Rahul Jariwala confirmed that all regulatory compliances were maintained during the quarter and nine-month period ended December 31, 2025.

Trident Texofab Limited announced robust financial results for the second quarter of fiscal year 2026, with significant top-line growth and margin improvement.

Key Highlights

• Revenue from operations grew 16% year-over-year to ₹3,063.46 lakhs in Q2 FY26
• Total income increased 6% to ₹3,102.56 lakhs
• EBITDA margin expanded substantially to 8.12%, up from -1.04% in Q2 FY25
• Profit after tax rose 12% to ₹112.77 lakhs

Strong Revenue Growth

Trident Texofab continued its growth momentum, with revenue from operations rising 16% compared to the same quarter last year. Total income for Q2 FY26 stood at ₹3,102.56 lakhs, marking a 6% year-over-year increase.

Significant Margin Expansion

The company reported a notable improvement in profitability, with EBITDA margin expanding to 8.12% in Q2 FY26 from -1.04% in Q2 FY25. This 916 basis point increase reflects enhanced operational efficiency.

Manufacturing Focus Drives Growth

Trident Texofab's shift towards manufacturing operations continues to be a key growth driver. The manufacturing division is now the core strength of the company's business, contributing to both revenue growth and margin improvement.

Management Commentary

The management highlighted the company's healthy financial performance, noting revenue growth on both year-over-year and sequential bases. They emphasized the manufacturing division's role as the core strength of operations and expressed satisfaction with the notable improvement in operating profitability margins.

Outlook

With its continued focus on manufacturing and improved operational metrics, Trident Texofab appears well-positioned for future growth. The company's ability to expand margins while growing revenue indicates strengthening fundamentals in its business model.

Investors will likely watch for sustained margin improvement and further growth in the manufacturing segment in coming quarters as indicators of Trident Texofab's long-term prospects.